Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Actalycabtagene Autoleucel
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Caring Cross
Deal Size : Undisclosed
Deal Type : Agreement
23andMe Initiates Phase 1 Clinical for Dual Mechanism Antibody 23ME-01473 Targeting ULBP6
Details : The agreement aims to develop and commercialize a multi-targeted chimeric antigen receptor T-cell immunotherapy, NexCAR19 (Actalycabtagene autoleucel), for the treatment of leukaemia and lymphoma.
Product Name : NexCAR19
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 05, 2024
Lead Product(s) : Actalycabtagene Autoleucel
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Caring Cross
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Actalycabtagene Autoleucel
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
India’s First Cell Therapy for Cancer Treatment Receives Regulatory Approval
Details : NexCAR19 (Actalycabtagene autoleucel) is an indigenously developed CD19-targeted CAR-T cell therapy for blood cancer. It is the first-of-its-kind, made-in-India product and is a major stride in advanced cell-and-gene therapies.
Product Name : NexCAR19
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 13, 2023
Lead Product(s) : Actalycabtagene Autoleucel
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
